David A. Siegel Fulcrum Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 420,200 shares of FULC stock, worth $2.61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

420,200

Previous 496,200 15.32%

Holding current value

$2.61 Million

Previous $3.35 Million 18.42%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $509,200 - $912,000	-76,000 Reduced 15.32%	420,200 $3.97 Million
Q4 2023 Feb 14, 2024	SELL	$3.18 - $6.86 $82,044 - $176,988	-25,800 Reduced 4.94%	496,200 $3.35 Million
Q3 2023 Nov 14, 2023	SELL	$3.25 - $6.08 $238,225 - $445,664	-73,300 Reduced 12.31%	522,000 $2.32 Million
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $751,901 - $1.26 Million	332,700 Added 126.69%	595,300 $1.96 Million
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $562,038 - $2.78 Million	198,600 Added 310.31%	262,600 $748,000

Q4 2022 Feb 14, 2023	BUY	$5.35 - $7.28 $73,295 - $99,736	13,700 Added 27.24%	64,000 $465,000
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $300,120 - $555,100	-61,000 Reduced 54.81%	50,300 $407,000
Q2 2022 Aug 15, 2022	BUY	$4.2 - $24.0 $108,360 - $619,200	25,800 Added 30.18%	111,300 $545,000
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $2.92 Million - $6.94 Million	-293,600 Reduced 77.45%	85,500 $2.02 Million
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $3.32 Million - $6.74 Million	236,900 Added 166.6%	379,100 $6.71 Million
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $1.04 Million - $4.4 Million	142,200 New	142,200 $4.01 Million

Others Institutions Holding FULC

# of Institutions

136

Shares Held

43.7M

Call Options Held

3.12M

Put Options Held

128K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $323M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account